Paths through unexplored territory

Feierliche Inbetriebnahme des Tellerseparators „Pathfinder“ und des Hochdruckhomogenisators „Panda plus“ am 2. Juni 2025 im PVZ mit Prof. Arno Kwade (r.h.) und Prof. Rainer Krull (2.v.l.h.) sowie Annette Wille (3.v.r.h.), Geschäftsführung GEA Germany GmbH. Bildnachweis: Karl Vorländer/TU Braunschweig / Ceremonial commissioning of the ‘Pathfinder’ plate separator and the ‘Panda plus’ high-pressure homogeniser on 2 June 2025 at the PVZ with Prof. Arno Kwade (right) and Prof. Rainer Krull (second from left) as well as Annette Wille (third from right), Managing Director of GEA Germany GmbH. Photo credits: Karl Vorländer/TU Braunschweig

Tellerseparator „Pathfinder“ im Biotechnikum des PVZ in Braunschweig. Bildnachweis: Jan-Angelus Meyer/TU Braunschweig / ‘Pathfinder’ disc separator in the biotechnology centre at the PVZ in Braunschweig. Photo credits: Jan-Angelus Meyer/TU Braunschweig

The Centre for Pharmaceutical Process Engineering (PVZ) at Technische Universität Braunschweig has expanded its biotechnology facility with a state-of-the-art plate separator from the GEA Group. With continuous progress in biopharmaceutical research, the need for high-performance technical infrastructure is also growing. A central process step in biotechnological processes is the efficient and precise separation of cells and culture supernatants, which can now be carried out gently and efficiently with the new large-scale equipment. This opens up new possibilities in bioprocess engineering and supports the complete mapping of the value chain of biotechnological processes on a pilot scale.

The new large-scale device was officially put into operation at the PVZ on 1 May 2025: The GEA Pathfinder separator is specially designed for biopharmaceutical pilot plants and enables throughputs of up to 200 litres per hour. From pre-culture and cultivation to cell separation and active ingredient purification, the biotechnological value chain can now be realised at the PVZ.

The Pathfinder enables extremely efficient cell harvesting from large bioreactors with volumes of up to 100 litres. The device achieves outstanding separation performance with up to 20,000 times the acceleration due to gravity and continuously removes even the finest particles and cell fragments from the cultivation media. Its hydrohermetic inlet ensures particularly gentle product handling – shear forces are minimised, which protects product quality. The self-cleaning drum enables fully automatic cleaning-in-place (CIP), while GMP-compliant certifications meet the requirements of pharmaceutical production.

This powerful complete package supports fast, scalable and reproducible process control – an essential prerequisite for the development of next-generation biopharmaceutical products.

Research for tomorrow’s medicine

Around 100 scientists from the fields of pharmacy, biotechnology, process engineering and other natural and engineering sciences work together on an interdisciplinary basis at the PVZ. The aim is to develop innovative manufacturing processes for individualised biopharmaceutical products. One focus of the ‘Pharmaceutical-Biological Process Engineering’ department is on the biotechnological production of active ingredients such as therapeutic proteins, antibodies for immunotherapy, enzymes for industrial biocatalysis and new antibiotics – key technologies for the medicine and pharmacy of the future.

Strategic partnership with GEA

In addition to basic research projects, the use of the new separator also forms the basis for application-oriented industrial research and development collaborations. Starting in summer 2025, two industrial projects led by Professor Rainer Krull and M.Sc. Jan-Angelus Meyer from the Institute of Bioprocess Engineering will begin, building directly on the expanded technical capabilities of the PVZ.

“The PVZ will thus offer expanded cooperation opportunities for partners from the pharmaceutical and biotechnology industries in the future – with the aim of jointly advancing practical and innovative research,” says Professor Rainer Krull from the Institute of Bioprocess Engineering at TU Braunschweig.